Related references
Note: Only part of the references are listed.Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Application of lag-time into exposure definitions to control for protopathic bias
H. Tamim et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
Felix M. Arellano et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults
David J. Margolis et al.
DERMATOLOGY (2007)
Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro
Frank S. Kalthoff et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2007)
The risk of lymphoma in patients with psoriasis
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
The use of topical calcineurin inhibitors in dermatology: Safety concerns - Report of the American Academy of Dermatology Association Task Force
TG Berger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides
L Vakeva et al.
ACTA DERMATO-VENEREOLOGICA (2005)
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
LF Eichenfield et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Share Paper
